Published in Leuk Lymphoma on February 01, 2010
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica (Cairo) (2013) 1.15
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia (2012) 1.07
TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk (2012) 0.96
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis (2013) 0.94
Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One (2010) 0.89
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One (2012) 0.85
Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn (2011) 0.84
Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget (2015) 0.84
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone (2015) 0.83
Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. J Cell Biochem (2016) 0.78
Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease. Int J Numer Method Biomed Eng (2014) 0.77
The role of osteoblasts in bone metastasis. J Bone Oncol (2016) 0.75
A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease. Int J Numer Method Biomed Eng (2015) 0.75
Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcif Tissue Int (2016) 0.75
Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci Transl Med (2016) 0.75
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Eph-ephrin bidirectional signaling in physiology and disease. Cell (2008) 7.12
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest (1998) 5.03
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab (2006) 4.33
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci U S A (2003) 2.65
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A (2004) 2.46
Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology (2002) 2.46
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem (2003) 2.44
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci (2006) 2.18
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood (2008) 2.05
Pathogenesis of myeloma bone disease. Leukemia (2008) 2.04
The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood (1999) 2.02
Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest (2002) 1.99
Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res (2004) 1.98
EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res (2008) 1.97
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia (2007) 1.86
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood (2007) 1.75
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol (2002) 1.74
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res (2009) 1.72
Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest (1998) 1.70
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood (2004) 1.70
Decorin prevents metastatic spreading of breast cancer. Oncogene (2005) 1.69
Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res (2003) 1.67
Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem (1996) 1.67
Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood (2006) 1.63
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood (2005) 1.59
The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia (2004) 1.57
Phenotype discovery by gene expression profiling: mapping of biological processes linked to BMP-2-mediated osteoblast differentiation. J Cell Biochem (2003) 1.56
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol (2006) 1.56
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol (2005) 1.56
Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer (2008) 1.51
Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem (2005) 1.50
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone (2007) 1.50
A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia (2007) 1.47
Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene (2002) 1.42
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol (1992) 1.39
Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest (1991) 1.38
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood (2005) 1.35
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood (2007) 1.32
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood (2003) 1.29
Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia (2009) 1.29
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol (2006) 1.27
The cell biology of bone metabolism. J Clin Pathol (2008) 1.26
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood (2009) 1.25
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood (2009) 1.21
Role of decorin in the antimyeloma effects of osteoblasts. Blood (2008) 1.19
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int J Med Sci (2008) 1.17
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol (2008) 1.13
Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer (2001) 1.13
Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res (2004) 1.10
Differential roles for small leucine-rich proteoglycans in bone formation. Eur Cell Mater (2003) 1.09
Role of osteoblast suppression in multiple myeloma. J Cell Biochem (2006) 1.09
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood (2009) 1.08
Growth factor control of bone mass. J Cell Biochem (2009) 1.07
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun (2005) 1.07
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am J Hematol (2009) 1.05
Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood (1995) 1.04
Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma (2006) 1.01
Role of the small leucine-rich proteoglycan (SLRP) family in pathological lesions and cancer cell growth. J Nippon Med Sch (2005) 0.97
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol (2007) 0.92
Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells. Mol Cancer Res (2008) 0.90
Does myeloma secrete an osteoblast inhibiting factor? J Bone Joint Surg Br (1989) 0.88
The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma (1999) 0.82